HCM - Hutchison China MediTech reports mixed Q4 earnings; initiates FY23 outlook

• Hutchison China MediTech press release ( NASDAQ: HCM ): FY GAAP EPADS of -$2.13 misses by $0.02 .
• Revenue of $426.4M (+19.7% Y/Y) beats by $16.62M .
• Cash, Cash Equivalents and Short-Term Investments were $631.0 million as of December 31, 2022 compared to $1,011.7 million as of December 31, 2021.
• We provide financial guidance for 2023 below reflecting expected revenue growth of ELUNATE ^® , SULANDA ^® and ORPATHYS ^® in China and out-licensing revenue. While we are not providing net cash flow guidance for 2023, we will extend our cash runway through partnering and strategic shifting to focus on the most advanced assets from our internal development pipeline.
• Expects Oncology/Immunology consolidated revenues of $450 – $550 million.

For further details see: